There is no cost or obligation to you. The complaint alleges that the defendants employed devices, schemes and artifices to defraud, while in possession of material adverse non-public information, in an effort to assure investors of Biogen's value and performance and continued substantial growth. In particular, the complaint alleges that the Company failed to disclose material information about the Company's business, particularly in regards to their Tecfidera drug treatment. In 2014, the MS Institute at Shepherd Center in Georgia, a prescriber of Tecfidera, began conducting blood tests of MS patients taking the drug.